Century Therapeutics, Inc.
IPSC evidence brief
What we can confirm
- BioSniper Score:
- 5.2 / 10
- Market Cap:
- $351.3M
What it means
What to watch
Prepared research question
What matters most for IPSC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IPSC
Century Therapeutics (IPSC) is a publicly traded biotechnology company developing iPSC-derived cell therapies for oncology, autoimmune diseases, and type 1 diabetes, with its most advanced program (CNTY-813) approaching an IND submission in Q4 2026.
Key risk: Capital depletion risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$351.3M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 clinical trials for Century Therapeutics, Inc..
Century Therapeutics (IPSC) is a publicly traded biotechnology company developing iPSC-derived cell therapies for oncology, autoimmune diseases, and type 1 diabetes, with its most advanced program (CNTY-813) approaching an IND submission in Q4 2026.
- Cash & equivalents of $49.6M as of 2026-06-30 [sec].
- Net income of -$34.5M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $232.3M as of 2026-06-30 [sec].
- CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes, completed a pre-IND meeting with the FDA; IND submission on track for Q4 2026 [news · 2026-08-12].
- CNTY-308, a CD19-targeted CAR-iT cell therapy for B-cell-mediated diseases, is in IND-enabling studies with expected clinical study initiation in 2026 [sec_mda · as of 2026-05-13].
What works
- Proprietary Allo-Evasion™ 5.0 platform designed to enable immune evasion of iPSC-derived cells, demonstrated in preclinical models for CNTY-813 [sec_mda · as of 2026-08-12].
- Broad pipeline across multiple cell types (islet cells, T cells, NK cells) from a single iPSC platform, potentially reducing manufacturing complexity [sec_mda · as of 2026-08-12].
- Scalable GMP manufacturing process established for CNTY-813, with three independent batches from a master cell bank [sec_mda · as of 2026-08-12].
What to weigh
- No approved products or significant product revenue; company expects to need additional financing to fund operations [sec_mda · as of 2026-08-12].
- Operating losses expected to increase substantially as preclinical and clinical activities expand [sec_mda · as of 2026-08-12].
- Cash runway estimated only into Q4 2027 as of November 2025, with no guarantee of meeting that timeline [news · 2025-11-13].
- All programs are in preclinical or early clinical stages; regulatory and clinical risks remain high [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
CNTY-813 IND submission on track for Q4 2026
“IND submission on track for 4Q 2026”
News · August 12, 2026
CNTY-813 preclinical data showed durable glucose control and immune evasion
“CNTY-813 preclinical data from oral presentation at ADA 2026 showed durable glucose control in vivo, immune evasion, and manufacturing success at clinical scale”
News · August 12, 2026
CNTY-308 is a CD19-targeted CAR-iT cell therapy in IND-enabling studies
“CNTY-308, a CD19-targeted CD4+/CD8+ ab CAR-iT cell therapy functionally comparable to primary T cells and engineered with Allo-Evasion™ 5.0”
SEC MD&A · May 13, 2026
Risks & what to watch (3)›
Key risks
- Capital depletion risk — Cash runway estimated only into Q4 2027; additional financing likely needed [news · 2025-11-13].
- Preclinical/clinical failure
- Regulatory delays
What to watch
- CNTY-813 IND submission in Q4 2026 and initial clinical data expected in H2 2027 [news · 2026-08-12].
- CNTY-308 clinical study initiation in 2026 [sec_mda · as of 2026-05-13].
- Cash runway updates and any new financing rounds [news · 2025-11-13].
- Preclinical data presentations at upcoming conferences (e.g., EASD 2026) [news · 2026-08-12].
Sources: News · SEC filings · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run Century Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Century Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.24 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 6 sells (180d)
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 6.7%
- Days to cover
- 6.3
- Shares short
- 10,289,543
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IPSC short interestGovernance
Frequently asked questions
What is the AI investment thesis for Century Therapeutics, Inc.?
Century Therapeutics (IPSC) is a publicly traded biotechnology company developing iPSC-derived cell therapies for oncology, autoimmune diseases, and type 1 diabetes, with its most advanced program (CNTY-813) approaching an IND submission in Q4 2026.
Who is the CEO of Century Therapeutics, Inc.?
Dr. Brent Pfeiffenberger M.B.A., Pharm.D. is the chief executive officer of Century Therapeutics, Inc. (IPSC).
Where is Century Therapeutics, Inc. headquartered?
Century Therapeutics, Inc. (IPSC) is headquartered in Philadelphia, PA, United States.
What therapeutic areas does Century Therapeutics, Inc. focus on?
Century Therapeutics, Inc. develops therapies across Oncology, Immunology, Dermatology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.